Dextech Medical AB (FRA:LQ0)

Market Cap	17.35M +43.0%
Revenue (ttm)	378.39K -2.1%
Net Income	-557.80K
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.8640
Previous Close	n/a
Day's Range	0.8640 - 0.8640
52-Week Range	0.5400 - 1.1200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About Dextech Medical AB

Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer in Sweden. The company’s lead candidate, OsteoDex, which has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, or the treatment of acromegaly,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 1
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LQ0

Financial Performance

In fiscal year 2025, Dextech Medical AB's revenue was 3.22 million, a decrease of -40.15% compared to the previous year's 5.39 million. Losses were -4.84 million, 2.96% more than in 2024.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 17, 2026

Data Sources Report a data error